Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AC 0682

Next Previous
Drug Profile

AC 0682

Alternative Names: AC-0682; AC682

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Accutar Biotechnology
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HER2 negative breast cancer

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Late-stage disease, Metastatic disease) in USA (PO)
  • 11 Apr 2024 Accutar Biotechnology terminates phase I trial HER2 negative breast cancer (Late-stage disease, Metastatic disease) in USA since the sponsor's development strategy was adjusted(PO) (NCT05080842)
  • 28 Sep 2023 Accutar Biotechnology terminates a phase I trial for HER2 negative breast cancer (Late stage disease, Metastatic disease, Second line therapy or greater) in China (PO), since the sponsor's development strategy was adjusted (NCT05489679)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top